HEALTHJul 13 · 02:53 UTCDAWN[email protected] (Imran Ayub)

Pricing delay raises shortage of medicine, counterfeiting risks

A delay in approving price revisions for 105 essential medicines in Pakistan has led to shortages and increased risks of counterfeit drugs. Manufacturers cite rising production costs and financial unsustainability, while experts warn of supply chain integrity threats as illegal suppliers fill the gap.

Nexus surfaces and summarizes. The full story lives at the source.

Mentioned

Drug Regulatory Authority of PakistanorganizationPakistan Chemists and Druggists AssociationorganizationFederal Governmentorganizationoral morphine capsulestopicstreptokinase injectionstopiccisplatintopiccarboplatintopicdoxorubicintopic

Spot something wrong with this article?Report a problem →

Forward this

Related Signal

Adjacent reporting

HEALTHMay 1 · 11:39 UTC
Medication shortage chaos: The vital drugs missing from Britain's pharmacy shelves - and experts warn the issue is about to get WORSE
HEALTHMay 12 · 18:18 UTC
STAT+: European Union inks a draft deal to boost local production of medicines and avoid shortages
HEALTHJun 9 · 20:46 UTC
STAT+: The shortage of many medicines in the U.S. remains a ‘systemic’ problem, a new analysis finds
HEALTHApr 24 · 17:08 UTC
British cancer patients set to face drug shortages within WEEKS as Iran war sends prices soaring, warn pharmacies